Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

corcept therapeutics - CORT

CORT

Close Chg Chg %
90.32 -1.89 -2.09%

Closed Market

88.43

-1.89 (2.09%)

Volume: 1.06M

Last Updated:

Oct 8, 2025, 4:00 PM EDT

Trade Now

Company Overview: corcept therapeutics - CORT

CORT Key Data

Open

$91.00

 Day Range

85.61 - 91.00

52 Week Range

42.01 - 117.33

 Market Cap

$9.52B

Shares Outstanding

105.37M

 Public Float

93.32M

Beta

0.46

 Rev. Per Employee

N/A

P/E Ratio

80.38

 EPS

$1.27

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

930.49K

  

CORT Performance

1 Week
 
 0.32%
 
1 Month
 
 21.35%
 
3 Months
 
 23.02%
 
1 Year
 
 94.65%
 
5 Years
 
 381.91%
 

CORT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About corcept therapeutics - CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

CORT At a Glance

Corcept Therapeutics, Inc.
101 Redwood Shores Parkway
Redwood City, California 94065
Phone 1-650-327-3270 Revenue 675.04M
Industry Pharmaceuticals: Major Net Income 139.73M
Sector Health Technology 2024 Sales Growth 39.941%
Fiscal Year-end 12 / 2025 Employees 500
View SEC Filings

CORT Valuation

P/E Current 80.377
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 40.924
Price to Sales Ratio 8.471
Price to Book Ratio 7.794
Price to Cash Flow Ratio 28.87
Enterprise Value to EBITDA 38.629
Enterprise Value to Sales 7.913
Total Debt to Enterprise Value 0.001

CORT Efficiency

Revenue/Employee 1,350,080.00
Income Per Employee 279,466.00
Receivables Turnover 11.623
Total Asset Turnover 0.923

CORT Liquidity

Current Ratio 3.35
Quick Ratio 3.262
Cash Ratio 2.723

CORT Profitability

Gross Margin 98.388
Operating Margin 20.288
Pretax Margin 23.923
Net Margin 20.70
Return on Assets 19.114
Return on Equity 23.558
Return on Total Capital 20.354
Return on Invested Capital 23.437

CORT Capital Structure

Total Debt to Total Equity 1.021
Total Debt to Total Capital 1.01
Total Debt to Total Assets 0.825
Long-Term Debt to Equity 0.899
Long-Term Debt to Total Capital 0.89
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Corcept Therapeutics - CORT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
365.98M 401.86M 482.38M 675.04M
Sales Growth
+3.42% +9.80% +20.04% +39.94%
Cost of Goods Sold (COGS) incl D&A
5.28M 5.38M 6.48M 10.88M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.07M 2.97M 1.04M 1.34M
Depreciation
3.07M 2.97M 1.04M 1.34M
Amortization of Intangibles
- - - -
-
COGS Growth
-5.39% +1.97% +20.35% +67.91%
Gross Income
360.70M 396.47M 475.89M 664.16M
Gross Income Growth
+3.56% +9.92% +20.03% +39.56%
Gross Profit Margin
+98.56% +98.66% +98.66% +98.39%
2021 2022 2023 2024 5-year trend
SG&A Expense
236.22M 283.84M 368.61M 527.21M
Research & Development
113.86M 130.99M 184.35M 246.89M
Other SG&A
122.36M 152.85M 184.26M 280.32M
SGA Growth
+7.33% +20.16% +29.87% +43.02%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
124.48M 112.63M 107.28M 136.95M
Non Operating Income/Expense
529.00K 3.56M 17.27M 24.54M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
125.01M 116.19M 124.56M 161.49M
Pretax Income Growth
-5.01% -7.05% +7.20% +29.65%
Pretax Margin
+34.16% +28.91% +25.82% +23.92%
Income Tax
12.49M 14.77M 18.42M 20.28M
Income Tax - Current - Domestic
8.11M 48.65M 47.85M 60.22M
Income Tax - Current - Foreign
41.00K 30.00K 56.00K 256.00K
Income Tax - Deferred - Domestic
4.79M (33.44M) (28.26M) (39.63M)
Income Tax - Deferred - Foreign
(446.00K) (469.00K) (1.24M) (564.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- (130.00K) (644.00K) (1.48M)
Consolidated Net Income
112.51M 101.29M 105.50M 139.73M
Minority Interest Expense
- - - -
-
Net Income
112.51M 101.29M 105.50M 139.73M
Net Income Growth
+6.13% -9.98% +4.15% +32.45%
Net Margin Growth
+30.74% +25.20% +21.87% +20.70%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
112.51M 101.29M 105.50M 139.73M
Preferred Dividends
- - - -
-
Net Income Available to Common
112.51M 101.29M 105.50M 139.73M
EPS (Basic)
0.9728 0.9485 1.0187 1.3536
EPS (Basic) Growth
+5.91% -2.50% +7.40% +32.88%
Basic Shares Outstanding
115.65M 106.79M 103.56M 103.23M
EPS (Diluted)
0.8932 0.8734 0.9441 1.2313
EPS (Diluted) Growth
+4.64% -2.22% +8.09% +30.42%
Diluted Shares Outstanding
125.96M 115.97M 111.74M 113.48M
EBITDA
127.54M 115.60M 108.32M 138.29M
EBITDA Growth
-2.22% -9.36% -6.30% +27.66%
EBITDA Margin
+34.85% +28.77% +22.46% +20.49%

Snapshot

Average Recommendation BUY Average Target Price 134.50
Number of Ratings 5 Current Quarters Estimate 0.445
FY Report Date 12 / 2025 Current Year's Estimate 1.08
Last Quarter’s Earnings 0.175 Median PE on CY Estimate N/A
Year Ago Earnings 1.23 Next Fiscal Year Estimate 2.22
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 4
Mean Estimate 0.45 0.28 1.08 2.22
High Estimates 0.71 0.58 1.38 3.31
Low Estimate 0.34 0.02 0.82 0.77
Coefficient of Variance 39.88 99.39 22.12 55.80

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 4
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Corcept Therapeutics - CORT

Date Name Shares Transaction Value
Aug 13, 2025 William Guyer Chief Development Officer 5,487 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $71.77 per share 393,801.99
Aug 13, 2025 William Guyer Chief Development Officer 350,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Daniel N. Swisher Director 2,200 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $14.08 per share 30,976.00
Aug 13, 2025 Daniel N. Swisher Director N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $72.3 per share 0.00
Aug 13, 2025 Daniel N. Swisher Director 5,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 William Guyer Chief Development Officer 40,494 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $21.65 per share 876,695.10
May 21, 2025 David L. Mahoney Director 30,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $6.55 per share 196,500.00
May 21, 2025 David L. Mahoney Director 27,352 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $74.21 per share 2,029,791.92
May 21, 2025 David L. Mahoney Director 3,523 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $74.17 per share 261,300.91
May 21, 2025 David L. Mahoney Director N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $74.65 per share 0.00
May 21, 2025 David L. Mahoney Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 Sean Maduck See Remarks 86,212 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $5.05 per share 435,370.60
Apr 4, 2025 Joseph K. Belanoff Chief Executive Officer; Director 2,982,335 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $94.72 per share 282,486,771.20
Apr 4, 2025 Sean Maduck See Remarks 85,622 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $102.16 per share 8,747,143.52
Apr 4, 2025 Sean Maduck See Remarks 91,212 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $101.43 per share 9,251,633.16
Apr 4, 2025 Sean Maduck See Remarks 106,345 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $100.26 per share 10,662,149.70
Apr 4, 2025 Sean Maduck See Remarks 185,622 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $8.27 per share 1,535,093.94
Apr 4, 2025 Joseph Douglas Lyon See Remarks 44,009 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $13.56 per share 596,762.04
Apr 4, 2025 Joseph Douglas Lyon See Remarks 119,009 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.52 per share 1,966,028.68
Apr 4, 2025 Sean Maduck See Remarks 85,622 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $114.55 per share 9,808,000.10

Corcept Therapeutics in the News